# Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in People With Persistent Symptoms During the Subacute Period After Traumatic Brain Injury

> **NCT02226848** · PHASE2 · WITHDRAWN · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)**

## Conditions studied

- Traumatic Brain Injury

## Interventions

- **DRUG:** Erythropoeitin

## Key facts

- **NCT ID:** NCT02226848
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-08-15
- **Primary completion:** 2017-05-31
- **Final completion:** 2017-05-31
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2018-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02226848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02226848, "Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in People With Persistent Symptoms During the Subacute Period After Traumatic Brain Injury". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02226848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*